1.Problems and strategies of safety management of laboratories in general hospitals
Qiang WU ; Zongtao CHEN ; Xiaohuang DU ; Aiping QI
Chinese Journal of Medical Science Research Management 2014;27(6):611-613
Technology platform is an important component of technical innovation of a hospital,and safety of laboratories is a prerequisite for building research hospitals.Proceeding from building a research hospital,this paper conducts in—depth analysis of the problems in the safety management of laboratories,in terms of awareness of safety,structural layout,staffing,routine management,biosafety,medical ethics,etc.,and discusses the strategies for the safety management of laboratories,in hope of providing theoretical support and valuable reference for the safety management of laboratories and the construction of research hospitals.
2.Revaluation of clopidogrel: let the data speak for themselves.
Li, LIU ; Fandian, ZENG ; Xiaohua, ZENG ; Qingmei, XUE ; Shaoping, NIE ; Cailian, KANG ; Jianhong, WU ; Qingyun, KANG ; Xingao, WANG ; Xiaoqing, LIU ; Tao, LI ; Jun, CHEN ; Qing, LI ; Rong, XU ; Xiaoyan, YANG ; Hui, KANG ; Fagang, JIANG ; Zongtao, LI ; XU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2010;30(3):299-306
Clopidogrel was believed to be superior to aspirin by the well-known CAPRIE trial. However, no other large clinical trials demonstrated the same results, but all focused on the combination use of clopidogrel with aspirin, and combination therapy in CREDO was called the "Emperor's New Clothes". However, no one overturned the results of these clinical trials by quantitatively analyzing them. We reviewed ten large-scale clinical trials about clopidogrel. On the basis of results of CAPRIE, CREDO and CHARISMA trials, we re-estimated their minimal sample sizes and their powers by three well-established statistical methodologies. From the results of CAPRIE, we inferred that the minimal sample size should be 85 086 or 84 968 but its power was only 30.70%. A huge gap existed. The same was also true of CREDO and CHARISMA trials. Moreover, in CAPRIE trial, 0 was included in the 95% confidence interval and 1 was included in the 95% confidence interval for the relative risk. There were some paradoxical data in CAPRIE trial. We are led to conclude that the results in CAPRIE, CREDO, and from the subgroup analysis in CHARISMA trials were questionable. These results failed to demonstrate that clopidogrel was superior to aspirin or that clopidogrel used in combination with aspirin was better than aspirin alone. The cost-effectiveness analyses by some previous studies were not reliable.
3.Revaluation of Clopidogrel: Let the Data Speak for Themselves
LIU LI ; ZENG FANDIAN ; ZENG XIAOHUA ; XUE QINGMEI ; NIE SHAOPING ; KANG CAILIAN ; WU JIANHONG ; KANG QINGYUN ; WANG XINGAO ; LIU XIAOQING ; LI TAO ; CHEN JUN ; LI QING ; XU RONG ; YANG XIAOYAN ; KANG HUI ; JIANG FAGANG ; LI ZONGTAO ; WANG XUWU ; ZHANG LI ; LONG YU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2010;30(3):299-306
Clopidogrel was believed to be superior to aspirin by the well-known CAPRIE trial. However, no other large clinical trials demonstrated the same results, but all focused on the combina-tion use of clopidogrel with aspirin, and combination therapy in CREDO was called the "Emperor's New Clothes". However, no one overturned the results of these clinical trials by quantitatively ana-lyzing them. We reviewed ten large-scale clinical trials about clopidogrel. On the basis of results of CAPRIE, CREDO and CHARISMA trials, we re-estimated their minimal sample sizes and their powers by three well-established statistical methodologies. From the results of CAPRIE, we inferred that the minimal sample size should be 85 086 or 84 968 but its power was only 30.70%. A huge gap existed. The same was also true of CREDO and CHARISMA trials. Moreover, in CAPRIE trial, 0 was included in the 95% confidence interval and 1 was included in the 95% confidence interval for the relative risk. There were some paradoxical data in CAPRIE trial. We are led to conclude that the results in CAPRIE, CREDO, and from the subgroup analysis in CHARISMA trials were questionable. These results failed to demonstrate that clopidogrel was superior to aspirin or that clopidogrel used in combination with aspirin was better than aspirin alone. The cost-effectiveness analyses by some pre-vious studies were not reliable.
4.Expression of PFKFB3 in brain glioma tissues and its effect on malignant biological behaviors of H4 cells
CHEN Xiangrong ; DU Jumei ; WU Zongtao
Chinese Journal of Cancer Biotherapy 2018;25(4):363-369
[Abstract] Objective: Toevaluatetheexpressionof6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3(PFKFB3) in malignant glioma tissues and the effects of inhibitor of PFKFB3(PFK15) on the proliferation, migration, invasion, clone formation and tumorigenesis of H4 cells. Methods: Malignant brain glioma tissues and corresponding paratumor tissues from 31 patients, who were hospitalized in Department of Neurosurgery,Ankang Hospital of Traditional Chinese Medicine during February 1, 2015 to January 31, 2016 for operative treatment, were collected for this study. Immunohistochemistry and western blotting assays were applied to detect the expression of PFKFB3 in collected tissues. PFKFB3 in H4 cells were blocked by PFK15 (1.25, 2.5, 5.0 μmol/L). The effect of PFK15 on proliferation, migration, clone formation and tumorigenesis of H4 cells were determined by MTT assay, EdU incorporation assay, wound healing assay, Transwell assay, colone formation assay and in vivo xenograft bearing nude mice model respectively. Results: Positive expression rate of PFKFB3 was significantly higher in malignant glioma tissues compared with normal adjacent tissues[(80.60±8.98)% vs (41.57±10.16)%, P<0.05]. The results of MTT assay and EdU incorporation assay indicated that PEK15 significantly inhibited the proliferation of H4 cells in a concentration dependent manner. The migration, invasion and clone formation activity of H4 cells were significantly reduced by treatment with PFK15 (all P<0.05). In tumor bearing nude mice, the tumor volume of mice treated with PFK15 was significantly smaller than that of mice from control group ([254.15±154.25] vs [801.52±224.25] mm3, P<0.05). Conclusion: PFKFB3 was highly expressed in malignant glioma tissues. Blocking of PFKFB3 by PFK15 significantly reduced the malignant biological behaviors and tumorigenesis of H4 cells in vitro and in vivo, which may serve as a promising target for the treatment of malignant gliomas.
5.Establishment and validation of population pharmacokinetic model of docetaxel in malignant tumor patients
Junping WANG ; Zhengyu WU ; Zhixia LOU ; Yuan YAO ; Tingting WU ; Zongtao HU
China Pharmacy 2022;33(18):2261-2265
OBJECTIVE To establis h and validate a population pharmacokinetic model of docetaxel in malignant tumor patients. METHODS The clinical data of malignant tumor patients treated with chemotherapy regimen containing docetaxel in our hospital from June 2019 to December 2021 were retrospectively collected . According to the results of blood concentration detection , based on the three -compartment model the nonlinear mixed effect model (NONMEM)was used ;covariates(age,weight,height, body surface area ,Karnofsky performance scale ,total protein ,albumin,total bilirubin ,aspartate aminotransferase ,alanine aminotransferase and serum creatinine )affecting clearance (CL)were screened by “forward inclusion and backward exclusion ”; the population pharmacokinetic model of docetaxel was established . The model was tested for goodness -of-fit diagnosis and internal validation by Bootstrap . RESULTS A total of 264 measured blood concentrations of 132 patients with malignant tumors during chemotherapy were included . The covariates that had significant effect on CL of docetaxel were serum creatinine and total bilirubin (P<0.01). The results of Bootstrap analysis (parameter median values and 95% confidence intervals )were close to predict results of the established model ;the final model estimated that the population typical value of docetaxel CL was 37.82 L/h. CONCLUSIONS The population pharmacokinetic model of docetaxel in malignant tumor patients is established successfully , which can be used for the formulation and optimization of clinical individualized regimen .